Scientific committee

Get to learn more about our scientific committee members in this section.

Dr. Ulrich Germing
Dr. Ulrich Germing

Prof. Germing, vice head of the Department of Haemotology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. His main focus is diagnosis, classification and prognosis of MDS, being trained in cytomorphology by Prof. Aul. He is head of the Düsseldorf MDS registry covering data on more than 5000 patients with MDS and leads the Düsseldorf MDS group since 1999.
He participates in international organisations such as The Myelodysplastic Syndromes Foundation and the International Prognostic Working Group in MDS. He is a member of the Clinical Advisory Commitee of the WHO and the European Leukemia Net. As a founder of The German-Austrian-Suisse MDS working group he aims at close collaboration between the different MDS centers. He is author or co-author of more than 220 articles.


Dr. John M. Bennett
Dr. John M. Bennett

Dr. Bennett is one of the world’s leading authorities on Myelodysplasia and was the founder of the MDS Foundation, as well as editor of the journal Leukemia Research. He is professor emeritus and former head of the medical oncology unit at the University of Rochester Medical Center and was a professor of oncology in medicine, pathology and laboratory medicine at the University of Rochester Medical School. He is serving, currently, as an attending Hematopathologist in the hematopathology Section of the Department of Pathology at University of Rochester Medical Center.

Full bio

Dr. Francesc Sole
Dr. Francesc Sole

Dr. Francesc Solé, from Barcelona (Spain), is an authority on Cytogenetics in Myelodysplasia (MDS). He was involved in the development of IPSS-R and is a member of the Steering Committee of IWG-PM (MDS Foundation). From 1996 until 2008, Dr. Solé was the coordinator of the Spanish Cytogenetics in Hematology Working Group. From 2004 until 2012 he was a member of the Steering Committee of Hematologic Quality Control in Eurogenest. Currently, he is the Scientific Director of the Institut de la Recerca contra la Leucèmia Josep Carreras-Campus ICO-GTiP, where he is also the Director of the Cytogenetic Platform Group and of the MDS Group. Dr. Solé holds Adjunct Professor positions at the Universitat Pompeu Fabra (Barcelona) and Universitat Autònoma de Barcelona (Bellaterra). He has published more than 200 papers. As a principal investigator he has coordinated 37 projects and has been involved in 82 collaborations.

LinkedIn

Dr. Detlef Haase
Dr. Detlef Haase

Prof. Haase is the Director of the Tumorcytogenetic Laboratory and of the Laboratory for Specialised Haematologic Diagnostics at the Department of Haemotology and Oncology, Georg-August-University of Göttingen, Germany. He participates in many international organisations such as The Myelodysplastic Syndromes Foundation, the International Cytogenetics Working Group and the International Prognostic Working Group in MDS (Co Chairman). He is a member of the European Leukemia Net Steering Committee and lead participant of it´s WP 11 (Cytogenetics). He is author or co-author of over 130 articles in international peer-reviewed journals and reviewer for scientific journals like Blood, Leukemia, Haematologica, Genes Chromosomes and Cancer, Leukemia Research and Annals of Hematology.

Full bio

Dr. Raphael Itzykson
Dr. Raphael Itzykson

Dr Itzykson is a physician-scientist working in the Hematology Department of Hopital Saint-Louis, Paris, France. His research focuses on the clinical and molecular prognostic factors of MDS, and on the pathogenesis of CMML. He has published articles in several peer-reviewed journals including Blood, Leukemia, Journal of Clinical Oncology and Haematologica.


Dr. Leonie Saft
Dr. Leonie Saft

Leonie Saft, M.D., Ph.D. is a specialist (consultant) in clinical pathology & cytology, and head of the Hematopathology and Flow cytometry Section at the Department of Pathology, Karolinska University Hospital, Solna, Stockholm, Sweden. She is member of the Nordic MDS Research Group and performs central review of Bone Marrow Biopsies within Nordic clinical MDS trials and participates in International Organisations such as the European Leukemia Network group (ELN) and the European Bone Marrow Study Group (EBMG).


Dr. Arjan van de Loosdrecht
Dr. Arjan van de Loosdrecht

Prof Arjan van de Loosdrecht is a professor of hematology at the department of Hematology, VUmc, Amsterdam. At the VUmc he is chair of the Scientific Committee (CWO) of the Cancer Center Amsterdam. He is author of over 160 peer-reviewed papers published in national and international journals particularly in the field of hematology (myeloid malignancies) and immunology. His particular scientific experiences and interests are on translational hematology. He is project leader/principle investigator of clinical (translational) programs dealing with the treatment of low-intermediate risk MDS. In addition, research focus on the role of flow cytometry in the diagnosis, prognostication and monitoring of MDS.
He is chair of the working group MDS of the Dutch Society of Cytometry on the implementation of flowcytometry in MDS and initiated a platform within the ELN on the implementation of flowcytometry in MDS in Europe.


Dr. Alan F. List
Dr. Alan F. List

Dr. Alan List is the President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents.

Full Bio

Dr. Esther Oliva
Dr. Esther Oliva

Esther Natalie Oliva earned degrees in Medicine and Surgery from the University of Messina, Italy, in 1990. In 1994, she received a degree in General Hematology from the same university. From 1991 to 1997, she earned a Mario Negri Institute research grant to conduct research at the Nephrology Unit of the Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" in Reggio Calabria, Italy. Since 1998 she has been a practicing haematologist at the Haematology Unit of the same hospital in Reggio Calabria, in charge of the Myelodysplastic Syndromes, Aplastic Anemia and Anemia section. Dr Oliva has developed a unique instrument, QOL-E, for the evaluation of quality of life in myelodysplastic syndromes. She has also developed and coordinated clinical trials in pharmacological research in hematology with a special focus on myelodysplastic syndromes, acute myeloid leukemia and on quality of life. She is the chair of the non-profit Association QOL-ONE for research on quality of life in Hematological patients. From 2015 she is the Chair of the EHA Scientific Working Group Quality of Life and Symptoms. In 2017 Dr. Oliva is an examiner for the EHA European Hematology Passport. She is an active member of the American Society of Hematology, the European Haematology Association, the International Society of Quality of Life and the Italian Society of Hematology and editor of the following Journals: American Journal of Blood Research and Clinical Reviews and Opinions.


Dr. Michael Pfeilstöcker
Dr. Michael Pfeilstöcker

Dr. Michael Pfeilstöcker is consultant at the Third Department for Internal Medicine – Hematology/Oncology, Hanusch Hospital, Vienna, Austria, where he also started a research career within the framework of the associated Institute for Leukemia Research now part of the Cluster Oncology of the L. Boltzmann Society. His research interests include theoretical and clinical studies in patients with myelodysplastic syndromes. A main focus of his research is in classification problems and prognostic factors in MDS. Furthermore, he is involved in clinical trials on new drugs in MDS including iron chelators. He is associate professor for medicine at the Vienna Medical University and chairs the MDS working group of the Austrian Society of Hematology and Oncology, which has established a fruitful ongoing international collaboration.

He has authored numerous articles in peer-reviewed journals including Blood and Leukemia and is a member of several professional organizations, including the American Society of Hematology.


Dr. Guido Kobbe
Dr. Guido Kobbe

Professor Kobbe is the head of the hematopoietic stem cell transplant program of the Department of Hematology, Oncology and Clinical Immunology at the University Hospital of the Heinrich Heine University Düsseldorf, Germany. His focus is allogeneic blood stem cell transplantation in MDS, Acute Leukemia and malignant Lymphoma and Myeloma. As a member of the Düsseldorf MDS research group he has a special interest in improving treatment results of allogeneic blood stem cell transplantation in patients with MDS. This includes the identification of suitable patients, design of transplant protocols and the prevention, detection and treatment of relapse. With a focus on clinical research he has authored and co-authored more than 150 peer reviewed articles.


Dr. Rafael Bejar
Dr. Rafael Bejar

Dr. Rafael Bejar is a physician-scientist at the UCSD Moores Cancer in La Jolla, California. After earning a BS in physics at the Massachusetts Institute of Technology, Dr. Bejar enrolled in the Medical Scientist Training Program at UCSD where he received his PhD and MD degrees. His internship in internal medicine was at the University of Chicago before moving to Boston where he completed his residency, and later a Chief Resident year at the Brigham and Women’s Hospital. Dr. Bejar’s hematology and oncology fellowship was at the Dana-Farber Cancer Institute where he began his research into the genetic basis of myelodysplastic syndromes. His work has helped identify how genetic mutations contribute to the development of MDS and how testing for these abnormalities can help physicians care for their patients with this disease. He is a writing member of the NCCN guidelines committee for MDS and is a member of the International Working Group for MDS molecular prognosis committee. Dr. Bejar has established an MDS Center of Excellence at UCSD where he cares for patients and continues to study the molecular mechanisms that drive the development of MDS.


Dr. Sophia Park
Dr. Sophia Park

Sophie PARK is Head of the MDS Clinical and Fundamental Research Program at Grenoble Alpes Hospital, Grenoble, France. She obtained her medical degree from Paris V René Descartes University, Cochin Hospital, Paris, before completing her residency in Hematology at the Assistance Publique des Hôpitaux de Paris, France. Professor Sophie PARK’s primary research focuses on MDS, treatment by erythropoiesis stimulating agents, AML, and basic research on the niche in MDS.
She has conducted several controlled, prospective multicentre studies that focus on AML, lower- risk MDS, ESA and iron chelation. She has published about 70 original articles in international peer-reviewed journals. And has delivered numerous lectures at local, national, and international conferences and symposia.


Dr. Blanca Xicoy
Dr. Blanca Xicoy

Dr. Blanca Xicoy is a Senior Hematologist, working in the Clinical Hematology Department from Institut Català d’Oncologia-Hospital Germans Trias i Pujol in Badalona (Barcelona).

Among her activities it should be highlighted first, clinical activity focused on chronic myeloproliferative neoplasms and marrow insufficiencies (myelodysplastic syndromes and medullary aplasia); second, research activity in these diseases as principal investigator of phase 2 to 4 clinical trials and collaboration in public and private research projects; third, active participation in national cooperative groups of these diseases (Spanish Group of Chronic Myeloid Leukemia, Spanish Group of Philadelphia Negative Chronic Myeloproliferative Neoplasms, Spanish Group of Myelodysplastic Syndromes) developing clinical guidelines of diagnosis and treatment of such diseases; fourth, one-year stay (2013-2014) at the Heinrich-Heine Universitäts-Klinikum, Düsseldorf, where the Düsseldorf MDS registry is located; fifth, active collaboration with the Josep Carreras Leukemia Research Institute collecting samples for the biobank as well as principal investigator and co-investigator from research projects within this institution; and sixth, Post-grade and Master in statistics in health sciences. As a result, she is author or co-author of more than 75 papers published in peer-review national and international journals.


Dr. Lucy A. Godley
Dr. Lucy A. Godley

Lucy A. Godley, MD, PhD, is an expert in the care and treatment of patients with diseases of the bone marrow, including leukemias, lymphomas and multiple myeloma. She also cares for patients undergoing stem cell transplantation and patients with benign hematologic conditions.

Dr. Godley has a special interest in the molecular basis of bone marrow malignancies and is an active researcher in the field. In her laboratory, Dr. Godley studies the basis for cancer cells' abnormal patterns of DNA methylation, as well as inherited forms of bone marrow cancers.

She has received numerous awards for her research, including the Howard Hughes Medical Institute Physician Postdoctoral Award, the Cancer and Leukemia Group B (CALGB) Foundation Clinical Research Award, the American Society of Clinical Oncology Young Investigator Award, the Cancer Research Foundation Young Investigator Award, the Schweppe Foundation Career Development Award and the Kimmel Scholar Award. She was inducted into the American Society of Clinical Investigation in 2012.

Dr. Godley's goal is to improve health through a deeper understanding and appreciation of science by integrating knowledge about fundamental networks within cancer cells and by bringing novel insights into the pathophysiology of her patients' diseases while offering them new treatment options.

Full bio

Dr. Norbert Gattermann
Dr. Norbert Gattermann

Dr. Gattermann is Professor of Medicine at the Department of Hematology, Oncology, and Clinical Immunology, and Managing Director of the University Cancer Center at Heinrich-Heine-University (HHU), Düsseldorf, Germany. He went to Medical School in Düsseldorf (HHU), London (The Royal Free Hospital), and Boston (Massachusetts General Hospital).

He received his M.D. and Ph.D. from Heinrich-Heine-University, Düsseldorf. He is board certified in Internal Medicine and Hematology/Oncology.

His research focus is on myelodysplastic syndromes, covering epidemiology, pathogenesis, prognosis, and therapy, with an emphasis on epigenetic treatment. He has initiated clinical trials with MDS patients, and acts as local PI for several studies. Scientific interests are related to the role of mitochondria in the pathogenesis of MDS and to problems of iron metabolism ranging from transfusional iron overload to the pathomechanism of mitochondrial iron overload in sideroblastic anemia. A further area of interest is chronic myeloid leukemia. Dr. Gattermann is a member of the German Society of Hematology and Oncology (DGHO), the American Society of Hematology (ASH), the German Competence Network „Acute and chronic leukemias“ (including MDS), and the European LeukemiaNet.University Cancer Center at Heinrich-Heine-University


Dr. Austin G Kulasekararaj
Dr. Austin G Kulasekararaj

Consultant Haematologist, King’s College Hospital, London, UK
Honorary Senior Clinical Lecturer, King’s College London, London, UK

Clinical Interests: MDS, Aplastic anaemia and bone marrow failures, PNH and myeloid malignancies. Leads the King’s National Paroxysmal Nocturnal Haemoglobinuria (PNH) service.

Translational Research: Molecular/immunological pathogenesis of MDS and aplastic anaemia, particular focus on overlap disorders. Bloodwise foundation and British Society of Haematology (BSH) senior clinical research fellow.

Clinical Trials: Passionate about delivery of clinical trials. Current National Coordinating Investigator for a number of Phase 1/2/3 clinical trials. Current drive is to bring novel therapies for PNH, AA, TP53 mutated myeloid neoplasms and improvement of thrombocytopenia.

Scienticific advisor for patient advocacy group (MDS UK) and member of the MDS NCRN working group. Member of the European Society for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party.

Authored/co-authored over 100 articles in peer-reviwed journals and has contributed to book chapters in major textbooks.


Dr. Patnaik
Dr. Patnaik

I am a Physician Scientist with the Division of Hematology and an Associate Professor in the Department of Medicine at the Mayo Clinic (Rochester, MN), with a specific interest in epigenetic dysregulation in clonal hematopoiesis (CHIP) and myeloid neoplasms; especially Chronic Myelomonocytic Leukemia (CMML). I am the chair of the acute leukemia and chronic myeloid neoplasms disease oriented group and am the director of the Epigenetics Developmental Laboratory. I have carried out important clinical, preclinical and prognostic work in CMML and have importantly demonstrated the high prevalence of epigenetic (TET2; Leukemia 2019) and chromatin dysregulation (ASXL1; Leukemia 2014) along with the negative prognostic impact of epigenetic mutations. This work has led to the development of the Mayo Molecular Model (Leukemia 2014); a contemporary prognostic model for patients with CMML. I am currently working on novel clinical agents and therapeutic vulnerabilities that can be exploited in this disease.


Dr. David Steensma
Dr. David Steensma

Dr. David Steensma is the Edward P. Evans Chair of MDS Research in the Division of Hematological Malignancies and Department of Medical Oncology at Dana-Farber Cancer Institute (DFCI), and a faculty member at Harvard Medical School (HMS). He directs the Center for Prevention of Progression at DFCI for patients with clonal hematopoiesis and other hematological malignancy precursor conditions, leads clinical research efforts at DFCI in myelodysplastic syndromes (MDS), and was the founding clinical director of the Regenerative Medicine and Stem Cell Biology course at HMS. He trained at the University of Chicago, Mayo Clinic and the Weatherall Institute of Molecular Medicine at the University of Oxford.


Dr. Platzbecker
Dr. Platzbecker

Prof. Dr. med. Uwe Platzbecker is currently the head of the medical Medical Clinic and Policlinic of Hematology, Cell Therapy and Hemostaseology at the University Hospital in Leipzig, Germany. He received his medical degree from the Medical Faculty of Technical University of Dresden in 1997. He was appointed the head of the Hematology section, University Hospital “Carl Gustav Carus” at the Technical University of Dresden from 2014 until 2018. He is a speaker of German MDS Study Group, a member of the International MDS Foundation’s Medical & Scientific Advisory Board, Chairman of the European Myelodysplastic Syndromes Cooperative Group (EMSCO) as well as the EHA MDS working party (SWG), a board Member of the SAL study group and has several publications in various world-renowned journals such as Blood and Lancet Oncology.


Josep Carreras
Gustave Roussy / VUmc
UTZ
UMG
University of Rochster
Karolinksa